| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
| ln Vitro |
To investigate if aggregates in mutant cells have misfolded β-sheet secondary structures, a straightforward screening method is to use Congo red histochemical staining. The histochemical dye Congo red exhibits a unique binding affinity for beta-sheet structures that overlap. By attaching to proteins in non-native conformations, wild-type HSPB1 should preserve protein homeostasis and stop substrate aggregation. Nevertheless, the T139M mutant fails to perform this function and instead causes misfolded proteins to accumulate, which Congo red targets for insertion between β-sheet structures. A straightforward method to investigate if aggregates in mutant cells have misfolded β-sheet secondary structures is to utilize Congo red histochemical staining [1].
|
|---|---|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Congo red, an azo dye derived from benzidine, and 2-azoxyfluorene, a derivative of 2-aminofluorene, were reduced during overnight incubation with a suspension of rat intestinal bacteria. HPLC and uv spectral analysis verified the presence of benzidine in the extracts of the Congo red incubations. ... Extracts of the Congo red incubations were mutagenic toward Salmonella typhimurium TA1538 in the presence of post-mitochondrial activating system, but Congo red was not mutagenic without this reductive pretreatment. ... The utility of the Ames test in screening for potential mutagens may be expanded by a reductive pretreatment utilizing cecal bacteria. |
| References | |
| Additional Infomation |
Congo Red is an indicator dye that is blue-violet at pH 3.0 and red at pH 5.0. It contains a 3,3'-(biphenyl-4,4'-diyldidiazene-2,1-diyl)bis(4-aminonaphthalene-1-sulfonate). It is functionally related to a 3,3'-(biphenyl-4,4'-diyldidiazene-2,1-diyl)bis(4-aminonaphthalene-1-sulfonic acid).
Congo Red is the sodium salt of benzidinediazo-bis-1-naphthylamine-4-sulfonic acid; a diazo dye that is red in alkaline solution and blue in acid solution and used especially as an indicator and as a biological stain. An acid dye used in testing for hydrochloric acid in gastric contents. It is also used histologically to test for AMYLOIDOSIS. |
| Molecular Formula |
C32H22N6NA2O6S2
|
|---|---|
| Molecular Weight |
696.6632
|
| Exact Mass |
696.083
|
| CAS # |
573-58-0
|
| PubChem CID |
11313
|
| Appearance |
Pink to red solid powder
|
| Density |
0.995 g/mL at 25 °C
|
| Melting Point |
>360 °C(lit.)
|
| LogP |
10.787
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
48
|
| Complexity |
1180
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
IQFVPQOLBLOTPF-UHFFFAOYSA-L
|
| InChi Code |
InChI=1S/C32H24N6O6S2.2Na/c33-31-25-7-3-1-5-23(25)29(45(39,40)41)17-27(31)37-35-21-13-9-19(10-14-21)20-11-15-22(16-12-20)36-38-28-18-30(46(42,43)44)24-6-2-4-8-26(24)32(28)34;;/h1-18H,33-34H2,(H,39,40,41)(H,42,43,44);;/q;2*+1/p-2
|
| Chemical Name |
disodium;4-amino-3-[[4-[4-[(1-amino-4-sulfonatonaphthalen-2-yl)diazenyl]phenyl]phenyl]diazenyl]naphthalene-1-sulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~20 mg/mL (~28.71 mM)
H2O : ~1 mg/mL (~1.44 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2 mg/mL (2.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2 mg/mL (2.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4354 mL | 7.1771 mL | 14.3542 mL | |
| 5 mM | 0.2871 mL | 1.4354 mL | 2.8708 mL | |
| 10 mM | 0.1435 mL | 0.7177 mL | 1.4354 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02610972 | COMPLETEDWITH RESULTS | Device: Congo Red test GV-005 | Preeclampsia | Gynuity Health Projects | 2018-12-01 | |
| NCT02381197 | UNKNOWN STATUS | Device: Congo Red Dot test | Preeclampsia | Gynuity Health Projects | 2017-01 | |
| NCT02611011 | COMPLETED | Device: Congo Red Test (GV-005) | Preeclampsia | Gynuity Health Projects | 2018-03-01 | |
| NCT02381210 | COMPLETED | Device: Congo Red Dot Test | Preeclampsia | Gynuity Health Projects | 2016-07 | |
| NCT02455544 | COMPLETED | Preeclampsia | Catalin S Buhimschi, MD | 2014-08 |
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
